Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: Potential for unmeasured confounding in studies of pioglitazone and bladder cancer

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 6, 2014, Pages 636-645

  Lewis, James D ^a   Habel, Laurel ^b   Quesenberry, Charles ^b   Mamtani, Ronac ^a   Peng, Tiffany ^b   Bilker, Warren B ^a   Hedderson, Monique ^b   Nessel, Lisa ^a   Vaughn, David J ^a   Strom, Brian L ^a,c   Ferrara, Assiamira ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DIVISION OF RESEARCH   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Bladder cancer; Diabetes mellitus; Pharmacoepidemiology; Proteinuria; Thiazolidinedione

Indexed keywords

ALBUMIN; CREATININE; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG INDUCED CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROTEINURIA; RACE; SMOKING; URINALYSIS; URINE LEVEL; ADULT; AGED; CHEMICALLY INDUCED; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; FOLLOW UP; MIDDLE AGED; UNITED STATES; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROTEINURIA; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84901832088     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3619     Document Type: Article

References (20)

1. Colmers IN, Bowker SL, Majumdar SR, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184: E675-E683.
2. Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2012; 98: 159-163.
3. Lewis JD, Ferrara A, Peng T, et al. Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
4. Moyer VA. Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2011; 155: 246-251.
5. American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34(Suppl 1): S11-S61.
6. Shen FC, Lee CT, Sun CK, et al. Prevalence of haematuria positively associated with urine albumin excretion in Type 2 diabetes. Diabet Med 2012; 29: 1178-1183.
7. Lewis J, Strom B, Bilker W, et al. Pioglitazone HCl (ACTOS) Clinical Study No. 01-03-TL-OPI-524. Cohort Study of Pioglitazone and Bladder Cancer in Patients with Diabetes Fourth Interim Analysis (8-Year) Report with Data from January 1, 1997 to December 31, 2010. 2012. http://www.encepp.eu/encepp/openAttachment.htm?field=documents.otherDocument[0]&id=2903
8. Liang KY, Zeger SL. Longitudinal Data-Analysis Using Generalized Linear-Models. Biometrika 1986; 73: 13-22.
9. Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010; 23: 253-262.
10. Wong G, Hayen A, Chapman JR, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009; 20: 1341-1350.
11. Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003; 14: 197-207.
12. Jorgensen L, Heuch I, Jenssen T, et al. Association of albuminuria and cancer incidence. J Am Soc Nephrol 2008; 19: 992-998.
13. Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001; 96: 3323-3328.
14. Sarafidis PA, Stafylas PC, Georgianos PI, et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010; 55: 835-847.
15. Woolhandler S, Pels RJ, Bor DH, et al. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA 1989; 262: 1214-1219.
16. Chen BT, Ooi BS, Tan KK, et al. Comparative studies of asymptomatic proteinuria and hematuria. Arch Intern Med 1974; 134: 901-905.
17. von Bonsdorff M, Koskenvuo K, Salmi HA, et al. Prevalence and causes of proteinuria in 20-year-old Finnish men. Scand J Urol Nephrol 1981; 15: 285-290.
18. Weiss NS. Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it.[see comment]. Am J Epidemiol 2003; 157: 957-961.
19. Lunetta M, Infantone L, Calogero AE, et al. Increased urinary albumin excretion is a marker of risk for retinopathy and coronary heart disease in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 40: 45-51.
20. Faillie JL, Petit P, Montastruc JL, et al. Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? Drug Saf 2013. doi:10.1007/s40264-013-0086-y.